PIP vs PrEP: HIV Prevention – Cost & Quality of Life Data (CROI 2026)

For individuals at low risk of HIV, a new approach to prevention—post-exposure prophylaxis kept “in-pocket” or PIP—is showing promise as an alternative to daily PrEP (pre-exposure prophylaxis). Data presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2026 suggest PIP may offer both healthcare savings and improvements in quality of life compared to traditional PrEP regimens.

Understanding the Landscape of HIV Prevention

Daily PrEP, involving a consistent regimen of HIV medication, has been a cornerstone of HIV prevention for years. However, it isn’t a perfect solution. Some individuals are hesitant to commence PrEP, while others, experiencing infrequent potential exposures—defined as one to four times per year—may not be considered ideal candidates for daily medication. This represents where PIP enters the conversation.

PIP involves providing a 28-day course of HIV medication to individuals at low risk, for them to retain at home and initiate if needed after a potential exposure. This strategy allows individuals to begin treatment within 72 hours of exposure, bypassing the demand for an immediate emergency department or clinic visit. The World Health Organization (WHO) has endorsed PIP as a viable prevention option, recognizing its potential to expand access to post-exposure care.

CROI 2026 Findings: PIP vs. PrEP

The research presented at CROI 2026, while not fully detailed in the available information, indicates a comparative advantage for PIP in specific contexts. The study suggests that PIP is associated with healthcare savings and improved quality of life outcomes when compared to PrEP. However, it’s critical to note that real-world data directly comparing the two approaches have been limited until recently. This new data begins to fill that gap.

The core benefit of PIP lies in its responsiveness. Unlike daily PrEP, which requires consistent adherence regardless of exposure risk, PIP is event-driven. It empowers individuals to seize control of their health and initiate treatment promptly when a potential exposure occurs. This approach may be particularly appealing to those who find the commitment of daily medication challenging or unnecessary given their risk profile.

What Does “Low Risk” Actually Mean?

Defining “low risk” is crucial. It generally refers to individuals who have infrequent potential exposures to HIV, such as those in stable, monogamous relationships with a partner who is HIV-negative, or those who occasionally engage in behaviors with a low probability of transmission. It’s essential to have an open and honest conversation with a healthcare provider to determine if PIP is an appropriate prevention strategy based on individual circumstances.

The Importance of Timely Intervention

The 72-hour window for initiating PIP after a potential exposure is critical. This timeframe aligns with the window during which post-exposure prophylaxis is most effective in preventing HIV infection. The ability to start treatment immediately, without waiting for a clinic visit, can significantly reduce anxiety and improve outcomes. However, it also places a responsibility on the individual to recognize a potential exposure and act quickly.

Limitations and Ongoing Research

While the initial findings are encouraging, it’s important to acknowledge the limitations of the current evidence. The data presented at CROI 2026 represents a step forward, but further research is needed to fully understand the long-term effectiveness and safety of PIP in diverse populations. Studies are needed to assess adherence rates, potential side effects and the impact of PIP on overall HIV transmission rates.

the success of PIP relies on individuals having access to the medication and understanding how and when to use it. Public health initiatives will be crucial to ensure equitable access and provide comprehensive education about PIP.

What Comes Next: Expanding Access and Refining Guidance

The endorsement of PIP by the WHO signals a growing acceptance of this approach as a valuable tool in the HIV prevention arsenal. However, translating this endorsement into widespread implementation will require ongoing efforts. Healthcare providers will need to be educated about PIP, and systems will need to be put in place to ensure that individuals at risk have access to the medication and the information they need to use it effectively.

Expect to see further research focusing on optimizing PIP protocols, identifying the populations that benefit most from this approach, and addressing potential barriers to access. Ongoing surveillance will be essential to monitor the impact of PIP on HIV incidence and to refine guidance as new evidence emerges. The conversation around HIV prevention is evolving, and PIP represents an exciting new chapter in that story.

For the most up-to-date information on HIV prevention, including PrEP and PIP, consult with a qualified healthcare provider or visit the Centers for Disease Control and Prevention (CDC) website.